- Emtricitabine/rilpivirine/tenofovir (trade
names Complera, Eviplera) is a fixed-dose
combination of
antiretroviral drugs for the
treatment of HIV/AIDS...
-
European Union in June 2016 (compare Emtricitabine/rilpivirine/tenofovir; (
Complera)) Emtricitabine/tenofovir
alafenamide (Descovy) —
approved in the United...
- emtricitabine/rilpivirine/tenofovir (
Complera), a three-drug HIV
regimen approved a year earlier. At the time of
Complera's approval,
there were
concerns about...
-
combinations include Atripla (tenofovir disoproxil/emtricitabine/efavirenz),
Complera (tenofovir disoproxil/emtricitabine/rilpivirine),
Stribild (tenofovir...
- president, and
Senior Director, Biology)
Products AmBisome Atripla Biktarvy Complera Cayston Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan...
-
Generic Attention deficit hyperactivity disorder Oct-2001 Mon-20XX 100
Complera Emtricitabine/Rilpivirine/Tenofovir
disoproxil fumarate 174,933 0.00% Gilead...
- Food and Drug
Administration (FDA) in
August 2011
under the
brand name
Complera, and was
approved for use in the
European Union with the
brand name Eviplera...
- of
combination therapies used to
treat HIV,
including Truvada, Atripla,
Complera, Stribild, Genvoya, Odefesey, Biktarvy, Descovy, and Symtuza.
Truvada is...
-
disoproxil efavirenz July 12, 2006
Gilead Sciences Bristol-Myers
Squibb Yes
Complera (US)
Eviplera (EU, RU)
emtricitabine tenofovir disoproxil rilpivirine August...
-
hepatitis B, e.g.
Viread (approved in 2001),
Truvada (2004),
Atripla (2006),
Complera/Eviplera (2011),
Stribild (2012),
Genvoya (2015),
Odefsey (2016), Descovy...
